Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial

被引：0
|
作者：
Jianhong Zhu
Wenxia Zhao
Dan Liang
Guocheng Li
Kaifeng Qiu
Junyan Wu
Jianfang Li
机构：
[1] Sun Yat-Sen Memorial Hospital,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation
[2] Sun Yat-sen University,Department of Pharmacy
[3] Sun-Yat-Sen Memorial Hospital,undefined
[4] Sun Yat-sen University,undefined
来源：
International Journal of Clinical Oncology | 2018年 / 23卷
关键词：
Anti-EGFR MAbs; Fatigue; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：389 / 399
页数：10
相关论文
共 50 条
  • [41] The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials
    Wang, Yang
    Li, Xiangyuan
    Huang, Tongmin
    Wang, Dongying
    He, Yujing
    Wei, Mengfei
    Chen, Yujie
    Zheng, Matao
    Shi, Yetan
    Zhang, Jianjian
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [42] The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials
    Yang Wang
    Xiangyuan Li
    Tongmin Huang
    Dongying Wang
    Yujing He
    Mengfei Wei
    Yujie Chen
    Matao Zheng
    Yetan Shi
    Jianjian Zhang
    World Journal of Surgical Oncology, 21
  • [43] Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials
    Ye, Lu
    Zhou, Fei
    Cheng, Dongdong
    Xie, Ming
    Yan, Xiaoli
    Xue, Yuyu
    Yang, Qian
    Jia, Rong
    Zhong, Lili
    Yang, Li
    Zou, Liqun
    Huang, Na
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [44] Risk of Bleeding from Primary Thromboprophylaxis (PTP) in Patients with Solid Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT)
    Thein, Kyaw Zin
    Tun, Aung M.
    Yeung, Sai-Ching J.
    Oo, Thein H.
    BLOOD, 2016, 128 (22)
  • [45] The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials
    Kim, Bum Jun
    Jeong, Jae Ho
    Kim, Hyeong Su
    Kim, Jung Han
    ONCOTARGET, 2017, 8 (60) : 102371 - 102380
  • [46] Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First-Line Treatment of Advanced NSCLC: A Meta-Analysis
    Stock, Gustavo
    Aguiar, Pedro, Jr.
    Santoro, Ilka
    Tadokoro, Hakaru
    De Mello, Ramon
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S333 - S334
  • [47] Risk of Venous Thromboembolism with Thalidomide in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Gray, Keriann N.
    Chu, David
    Wu, Shenhong
    Lin, Richard Z.
    BLOOD, 2008, 112 (11) : 1305 - 1306
  • [48] Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials
    Li, Jing
    Zhang, Zhifeng
    JOURNAL OF CHEMOTHERAPY, 2021, 33 (07) : 452 - 461
  • [49] Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Xiaona Lu
    Yuyao Li
    Yue Li
    Xuemei Zhang
    Jia Shi
    Hai Feng
    Zhuo Yu
    Yueqiu Gao
    BMC Cancer, 23
  • [50] Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
    Lu, Xiaona
    Li, Yuyao
    Li, Yue
    Zhang, Xuemei
    Shi, Jia
    Feng, Hai
    Yu, Zhuo
    Gao, Yueqiu
    BMC CANCER, 2023, 23 (01)
12345